- Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development - - Parallel translational initiative to…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has…
ERAS-801 has now received ODD in addition to FDA Fast Track Designation Initial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, June…
New York, USA, June 21, 2023 (GLOBE NEWSWIRE) -- Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+…